Literature DB >> 20815769

Does radiotherapy increase oxidative stress? A study with nasopharyngeal cancer patients revealing anomalies in isoprostanes measurements.

Keith H C Lim1, Chung-Yung J Lee, Arul Earnest, Raymond C S Seet, Barry Halliwell.   

Abstract

This study aimed to examine if exposure to ionizing radiation during clinical radiotherapy (RT) causes increased oxidative damage. Seven patients with nasopharyngeal cancer (NPC) who underwent RT took part in this controlled-trial study. Blood and urine samples were obtained for F(2)-isoprostanes (F(2)-IsoPs) measurement. Urinary F(2)-IsoPs levels were elevated pre-treatment and remained high (but did not increase) during treatment, but decreased to the normal range after treatment. Plasma F(2)-IsoPs decreased significantly after the start of treatment before rising midway through treatment. Levels decreased significantly to below baseline following treatment. However, the patients were observed to have substantially lower levels of plasma esterified arachidonic acid (AA) residues than controls. The data shows that NPC is associated with elevated F(2)-isoprostanes in urine and in plasma after correction for decreased AA levels. RT did not increase these levels and, indeed, was associated with falls in F(2)-IsoPs. The validity and usefulness of correction of plasma F(2)-IsoPs for lowered AA levels is discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20815769     DOI: 10.3109/10715762.2010.499906

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  2 in total

Review 1.  Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation.

Authors:  Dawid Przystupski; Marek Ussowicz
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

2.  The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells.

Authors:  Chun Li; Saeed M Hashimi; Siyu Cao; Albert S Mellick; Wei Duan; David Good; Ming Q Wei
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-30       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.